

IN THE CLAIMS:

Amend the claims as follows:

Claims 1-13 (Canceled).

14. (Previously Presented) An isolated polypeptide of up to 15 amino acids in length which includes the sequence WXXWXF (SEQ ID NO:9) where each X is independently any amino acid selected from G, A, I, L, V, S, T, K, R or H.

15. (Previously Presented) The polypeptide of claim 14 wherein said sequence is WXXWHF (SEQ ID NO:11); where each X is independently any amino acid selected from G, A, I, L, V, S, T, or R.

16. (Currently Amended) The polypeptide of claim 15 wherein said sequence is WVRWHF (SEQ ID NO:2) ~~or a fragment thereof capable of binding to an E2F DNA-binding site.~~

17. (Previously Presented) An isolated polypeptide WVRWHF (SEQ ID NO:2) or a variant thereof, which variant comprises from one or two amino acid substitutions, or three conservative amino acid substitutions, and which is capable of binding to an E2F DNA-binding site.

18. (Previously Presented) The polypeptide of claim 14 which inhibits the binding of an E2F protein to an E2F DNA binding site with an *in vitro* IC₅₀ of less than 100µM.

19. (Previously Presented) The polypeptide of claim 16 which inhibits the binding of an E2F protein to an E2F DNA binding site with an *in vitro* IC₅₀ of less than 100µM.

20. (Previously Presented) A polypeptide which comprises a first portion which has the amino acid sequence of a polypeptide of up to 15 amino acids in length which includes the sequence WXXWXF (SEQ ID NO:9) where each X is independently any amino acid selected from G, A, I, L, V, S, T, K, R, H or F, said polypeptide further comprising a second portion, attached to the N- or C-terminus of the first portion, which comprises a sequence of amino acids not naturally contiguous to the first portion, said second portion comprising a membrane translocation sequence.

21. (Previously Presented) A polypeptide which comprises a first portion which has the amino acid sequence of a polypeptide of up to 15 amino acids in length which includes the sequence WXXWXF (SEQ ID NO:9) where each X is independently any amino acid selected from G, A, I, L, V, S, T, K, R, H or F, and said polypeptide inhibits the binding of an E2F protein to an E2F binding site with an *in vitro* IC₅₀ of less than 100µM, said polypeptide further comprising a second portion, attached to the N- or C-terminus of the first portion, which comprises a sequence of amino acids not naturally contiguous to the first portion, said second portion comprising a membrane translocation sequence.

22. (Previously Presented) A composition comprising the polypeptide of claim 14 in association with a carrier or diluent.

23. (Previously Presented) A composition comprising the polypeptide of claim 16 in association with a carrier or diluent.

24. (Previously Presented) A multiple antigen peptide of the structure $\text{Pep}_4\text{-Lys}_2\text{-Lys-X}$, where Pep is a polypeptide of up to 15 amino acids in length which includes the sequence WXXWXF (SEQ ID NO:9) where each X is independently any amino acid selected from G, A, I, L, V, S, T, K, R, H or F, Lys is lysine and X is a terminal group.

25. (Previously Presented) A multiple antigen peptide of the structure $\text{Pep}_4\text{-Lys}_2\text{-Lys-X}$, where Pep is a polypeptide of up to 15 amino acids in length which includes the sequence WVRWHF (SEQ ID NO:2) or a fragment thereof capable of binding to an E2F DNA-binding site, Lys is lysine and X is a terminal group.

26. (Withdrawn) ~~A method~~ An in vitro method of inhibiting the growth of a eukaryotic cell which comprises bringing the cell into contact with the polypeptide of claim 14 under conditions to provide for apoptosis.

27. (Withdrawn) ~~A method~~ An in vitro method of inhibiting the growth of a eukaryotic cell which comprises bringing the cell into contact with the polypeptide of claim 16 under conditions to provide for apoptosis.

28. (Withdrawn) ~~A method~~ An in vitro method of inhibiting the growth of a eukaryotic cell which comprises bringing the cell into contact with the polypeptide of claim 20 under conditions to provide for apoptosis.

29. (Withdrawn) ~~A method~~ An in vitro method of inhibiting the growth of a eukaryotic cell which comprises bringing the cell into contact with the polypeptide of claim 21 under conditions to provide for apoptosis.

30. (Withdrawn) ~~A method~~ An in vitro method of inhibiting the growth of a eukaryotic cell which comprises bringing the cell into contact with the polypeptide of claim 24 under conditions to provide for apoptosis.

31. (Withdrawn) ~~A method~~ An in vitro method of inhibiting the growth of a eukaryotic cell which comprises bringing the cell into contact with the polypeptide of claim 25 under conditions to provide for apoptosis